Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn's disease: results of 2 Phase 2b randomised placebo-controlled trials

被引：0
|
作者：
Panes, J. [1 ]
Moscariello, M. [2 ]
Maller, E. [2 ]
Chan, G. [2 ]
Wang, W. [2 ]
Healey, P. [3 ]
机构：
[1] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP053
引用
收藏
页码：S60 / S61
页数：2
相关论文
共 50 条
  • [31] Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study
    Roeth, Alexander
    Broome, Catherine M.
    Barcellini, Wilma
    Jilma, Bernd
    Hill, Quentin A.
    Cella, David
    Tvedt, Tor Henrik Anderson
    Yamaguchi, Masaki
    Lee, Michelle
    Shafer, Frank
    Wardecki, Marek
    Jiang, Xiaoyu
    Patel, Parija
    Joly, Florence
    Weitz, Ilene C.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (03) : 280 - 288
  • [32] Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
    Louis, Edouard
    Lofberg, Robert
    Reinisch, Walter
    Camez, Anne
    Yang, Mei
    Pollack, Paul F.
    Chen, Naijun
    Chao, Jingdong
    Mulani, Parvez M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2013, 7 (01): : 34 - 43
  • [33] Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
    Sandborn, William J.
    Danese, Silvio
    Leszczyszyn, Jaroslaw
    Romatowski, Jacek
    Altintas, Engin
    Peeva, Elena
    Hassan-Zahraee, Mina
    Vincent, Michael S.
    Reddy, Padmalatha S.
    Banfield, Christopher
    Salganik, Mikhail
    Banerjee, Anindita
    Gale, Jeremy D.
    Hung, Kenneth E.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2616 - 2628
  • [34] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Esfandiari, Ehsanollah
    Mano, Hirotaka
    Arai, Takahiro
    Kabashima, Kenji
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [35] Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
    Thaci, D.
    Kimball, A.
    Foley, P.
    Poulin, Y.
    Levi, E.
    Chen, R.
    Feldman, S. R.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 498 - 506
  • [36] Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial
    Atreya, Raja
    Peyrin-Biroulet, Laurent
    Klymenko, Andrii
    Augustyn, Monica
    Bakulin, Igor
    Slankamenac, Dusan
    Miheller, Pal
    Gasbarrini, Antonio
    Hebuterne, Xavier
    Arnesson, Karin
    Knittel, Thomas
    Kowalski, Jan
    Neurath, Markus F.
    Sandborn, William J.
    Reinisch, Walter
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (12): : 1063 - 1075
  • [37] Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
    Gossec, Laure
    Mease, Philip
    Gottlieb, Alice
    Assudani, Deepak
    Coarse, Jason
    Ink, Barbara
    Coates, Laura
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [38] EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    Van der Heijde, D.
    Gensler, L. S.
    Deodhar, A.
    Baraliakos, X.
    Poddubnyy, D.
    Kivitz, A.
    Farmer, M. K.
    Baeten, D.
    Goldammer, N.
    Coarse, J.
    Oortgiesen, M.
    Dougados, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 68 - 69
  • [39] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
  • [40] Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
    Brightling, Christopher E.
    Chanez, Pascal
    Leigh, Richard
    O'Byrne, Paul M.
    Korn, Stephanie
    She, Dewei
    May, Richard D.
    Streicher, Katie
    Ranade, Koustubh
    Piper, Edward
    [J]. LANCET RESPIRATORY MEDICINE, 2015, 3 (09): : 692 - 701
12345